U.S., Nov. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07251556) titled 'GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis' on Sept. 26.
Brief Summary: Background Psoriatic arthritis (PsA) patients are at increased risk of cardiovascular disease. Glucagon-Like Peptide-1 (GLP-1) receptor agonists are cardiovascular protective in diabetics. They have also anti-inflammatory properties. It is hypothesized GLP-1 receptor agonists can prevent the progression of atherosclerosis due to the combination of metabolic factors and disease activity control in non-diabetic PsA patients.
Objectives To investigate the vascular effects of GLP-1 receptor agonists in PsA patients without diabetes. T...